Drug intelligence / Profile preview

Xuanfei Baidu

Development stage
Phase 2
Lead developer
Buchang Pharmaceutical Group
Administration
Oral
01

Overview

Xuanfei Baidu is a traditional Chinese medicine (TCM) formula developed specifically for treating COVID-19. It was designed by Academician Zhang Boli and Professor Liu Qingquan during the COVID-19 pandemic in China. The formula is available in different forms, including decoction (XFBD) and granule formulations. Xuanfei Baidu consists of 13 Chinese medicinal herbs: Ephedrae Herba (Mahuang), Gypsum Fibrosum (Shigao), Atractylodis Rhizoma (Cangzhu) (stir-baked with bran), Pogostemonis Herba (Guanghuoxiang), Artemisiae Annuae Herba (Qinghao), Polygoni Cuspidati Rhizoma et Radix (Huzhang), Verbenae Herba (Mabiancao), Coix Seed (Yiyiren), Phragmitis Rhizoma (Lugen), Descurainiae Semen Lepidii Semen (Tinglizi), Armeniacae Semen Amarum (Kuxingren), Citri Grandis Exocarpium (Huajuhong), Glycyrrhizae Radix et Rhizoma (Gancao). Xuanfei Baidu is recognized as one of the "three medicines and three prescriptions" recommended for COVID-19 treatment in China's national diagnosis and treatment guidelines. It has shown efficacy in shortening the duration from positive to negative SARS-CoV-2 nucleic acid tests, reducing hospitalization duration, improving clinical symptoms including fever, fatigue, cough, and appetite, preventing progression from moderate to severe disease states, and increasing white blood cell and lymphocyte counts. Research indicates that Xuanfei Baidu works through multiple mechanisms: anti-inflammatory effects (regulating macrophage-mediated immune inflammation, reducing NLRP3 inflammasome activation, inhibiting IL-6/STAT3 signaling pathway), mitochondrial dynamics regulation, and host metabolism modulation. According to traditional Chinese medicine theory, Xuanfei Baidu has the efficacy of "promoting the lung and resolving dampness, clearing heat and removing pathogeneses, purging the lung and depoisoning". It is specifically indicated for the TCM syndrome of "damp-toxin constraint in the lungs". Clinical studies have reported good safety with no serious adverse events.

Brand names
Xuanfei Baidu Granule
Other names
Xuanfei Baidu DecoctionXuanfei Baidu granuleXFBDXuan Fei Bai Du
02

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on Xuanfei Baidu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xuanfei Baidu.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call